June 3, 2016
Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer

February 8, 2013
OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-line Treatment for Patients With ROS1-Positive Non-Small Cell Lung Cancer